Endo International PLC (NASDAQ:ENDP) Forecasted to Post FY2023 Earnings of $0.86 Per Share

Share on StockTwits

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) – Analysts at Svb Leerink boosted their FY2023 EPS estimates for shares of Endo International in a research report issued on Wednesday, November 6th. Svb Leerink analyst A. Fadia now forecasts that the company will earn $0.86 per share for the year, up from their prior estimate of $0.81.

A number of other analysts have also weighed in on ENDP. Mizuho reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research note on Wednesday, August 7th. ValuEngine lowered shares of Endo International from a “hold” rating to a “sell” rating in a research note on Thursday. BidaskClub raised shares of Endo International from a “strong sell” rating to a “sell” rating in a research note on Friday, October 18th. Royal Bank of Canada reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research note on Thursday, August 8th. Finally, Morgan Stanley set a $2.00 price objective on shares of Endo International and gave the stock a “sell” rating in a research note on Friday, August 9th. Four investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $7.78.

ENDP traded up $0.10 during trading hours on Friday, hitting $4.33. The company’s stock had a trading volume of 5,829,800 shares, compared to its average volume of 5,703,535. Endo International has a 12 month low of $1.97 and a 12 month high of $13.75. The business’s 50-day moving average price is $4.02 and its 200-day moving average price is $4.34. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 1.50 and a beta of 1.41.

Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.53 by $0.07. Endo International had a negative net margin of 16.89% and a negative return on equity of 99.08%. The company had revenue of $729.00 million for the quarter, compared to analysts’ expectations of $709.01 million. During the same quarter in the previous year, the business posted $0.71 earnings per share. Endo International’s quarterly revenue was down 2.1% on a year-over-year basis.

Hedge funds have recently added to or reduced their stakes in the business. Paloma Partners Management Co acquired a new position in shares of Endo International during the second quarter valued at about $98,000. Meeder Asset Management Inc. increased its holdings in shares of Endo International by 47.1% during the second quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock valued at $156,000 after acquiring an additional 12,127 shares in the last quarter. Nisa Investment Advisors LLC increased its holdings in shares of Endo International by 14.5% during the third quarter. Nisa Investment Advisors LLC now owns 50,690 shares of the company’s stock valued at $163,000 after acquiring an additional 6,434 shares in the last quarter. Commonwealth Bank of Australia increased its holdings in shares of Endo International by 41.6% during the second quarter. Commonwealth Bank of Australia now owns 66,400 shares of the company’s stock valued at $273,000 after acquiring an additional 19,500 shares in the last quarter. Finally, Hunter Associates Investment Management LLC increased its holdings in shares of Endo International by 37.4% during the second quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock valued at $388,000 after acquiring an additional 25,625 shares in the last quarter. 95.20% of the stock is owned by institutional investors and hedge funds.

In other Endo International news, Director Roger H. Kimmel sold 25,000 shares of the stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $4.09, for a total transaction of $102,250.00. Following the completion of the sale, the director now directly owns 123,309 shares of the company’s stock, valued at $504,333.81. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 1.50% of the company’s stock.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Further Reading: Investing in Dividend Stocks

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.